Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 488 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Promethazine Clear all
Recruiting Phase 1 Interventional

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

NCT06211335
View directory record Official record
Conditions
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma
Interventions
Losartan, Pembrolizumab, Stereotactic Body Radiation Therapy
Drug · Biological · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Sacramento, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Completed No phase listed Observational

Case-Control Study of Pesticides and Childhood Leukemia

NCT00342888
View directory record Official record
Conditions
Leukemia
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 8 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Terminated Phase 2 Interventional

Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis

NCT02606994
View directory record Official record
Conditions
Mucositis, Neoplasms
Interventions
Oral Defense Toothpaste, Crest Toothpaste, Magic Mouth Rinse
Drug
Lead sponsor
Oral Defense, LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 20, 2026, 4:07 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Lidocaine Versus Diphenhydramine to Achieve Local Anesthesia for Laceration Repairs

NCT06910241
View directory record Official record
Conditions
Laceration of Skin
Interventions
Lidocaine, Diphenhydramine
Drug
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Terminated Phase 2Phase 3 Interventional

Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)

NCT02410005
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Calcitriol, Losartan
Dietary Supplement · Drug
Lead sponsor
Weill Cornell Medical College in Qatar
Other
Eligibility
21 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 20, 2026, 4:07 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer

NCT00226941
View directory record Official record
Conditions
Rectal Cancer, Colo-rectal Cancer
Interventions
Cetuximab, Oxaliplatin, Capecitabine, Radiotherapy, Diphenhydramine hydrochloride (HCl)
Drug · Radiation
Lead sponsor
George Albert Fisher
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 20, 2026, 4:07 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of Promethazine for Treatment of Diabetic Gastroparesis

NCT02130622
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Promethazine, Sugar pill
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 20, 2026, 4:07 PM EDT
Recruiting Phase 1 Interventional

The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)

NCT06070649
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Alcohol-Related Disorders, Alcohol Use
Interventions
0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion, 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion, 25 mg Diphenhydramine (5 min) + Normal Saline
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

NCT00795132
View directory record Official record
Conditions
Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions
Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

NCT00635232
View directory record Official record
Conditions
Hypertension
Interventions
irbesartan, placebo, PS433540
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
40
States / cities
Pell City, Alabama • Tempe, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 2Phase 3 Interventional

Risk Reduction for Alzheimer's Disease

NCT02913664
View directory record Official record
Conditions
Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions
Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise
Drug · Behavioral · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 85 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 4 Interventional Results available

The Montefiore Metoclopramide Study

NCT00475306
View directory record Official record
Conditions
Nausea, Extrapyramidal Symptoms
Interventions
metoclopramide 10 mg, Diphenhydramine 25 mg, Placebo, Metoclopramide 20 mg
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2012 · Synced Oct 20, 2026, 4:07 PM EDT
Recruiting Phase 2 Interventional

Losartan to Improve Outcomes After Multi-ligament Knee Injury

NCT06933706
View directory record Official record
Conditions
Multi-ligament Knee Injury
Interventions
losartan 25 mg, Placebo capsule
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Lexington, Kentucky • Bethesda, Maryland • Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Voxelotor CYP and Transporter Cocktail Interaction Study

NCT05981365
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor, Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, Metformin, Furosemide, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer

NCT00103207
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
157
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 107 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 20, 2026, 4:07 PM EDT
Recruiting Phase 3 Interventional

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

NCT06150560
View directory record Official record
Conditions
Coarctation of Aorta, High Blood Pressure
Interventions
Losartan, Amlodipine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Terminated Phase 4 Interventional

Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients

NCT03490396
View directory record Official record
Conditions
Oral Mucositis
Interventions
Gelclair, First® Mouthwash BLM
Device · Combination Product
Lead sponsor
Midatech Pharma US Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 20, 2026, 4:07 PM EDT
Enrolling by invitation Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fasted Conditions

NCT01216852
View directory record Official record
Conditions
Hypertension
Interventions
Losartan Potassium
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 4:07 PM EDT
Not yet recruiting Phase 4 Interventional

Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction

NCT07135687
View directory record Official record
Conditions
ACL Injury, ACL Reconstruction, Scar Formation
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 3 Interventional

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

NCT00281593
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan, Ramipril
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
70
States / cities
Glendale, Arizona • Tempe, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 20, 2026, 4:07 PM EDT
Active, not recruiting Phase 2 Interventional

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

NCT05331144
View directory record Official record
Conditions
Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
Interventions
Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP
Drug · Other
Lead sponsor
Rong Zhang
Other
Eligibility
60 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Not listed Phase 2 Interventional

Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)

NCT00699036
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
Interventions
avandia, metformin, losartan
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2009 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria

NCT02935699
View directory record Official record
Conditions
Acute Urticaria
Interventions
Test Drug (JDP-205), Active Control (Diphenhydramine)
Drug
Lead sponsor
JDP Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 20, 2026, 4:07 PM EDT